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Abstract
Background: Approximately 5-10% of breast cancers are hereditary. Among hereditary syndromes, Hereditary Breast
and Ovarian Cancer Syndrome (HBOC) and Li-Fraumeni Syndrome (LFS) have received the most attention. HBOC is
due to mutations in the BRCA1 and BRCA2 genes and is characterized by breast adenocarcinoma and/or epithelial
ovarian carcinoma. LFS is associated with germline mutations in TP53; the most frequent cancer types associated
with this syndrome are sarcoma, breast cancer, leukemia, brain tumors and adrenocortical carcinomas. Other
cancers related to LFS are found at lower frequencies. In Brazil, especially in the southern part of the country, a
specific mutation in the TP53 gene, TP53 p.R337H, occurs at a high frequency in childhood adrenocortical tumors. It
has been proposed that this mutation increases breast cancer risk in southern Brazilian women.
Methods: We carried out a case-control study to determine the prevalence of the TP53 p.R337H mutation in 28
female cancer patients attended at the Cancer Genetic Counseling Service of the General Hospital of the University
of São Paulo Medical School of Ribeirão Preto who fulfilled Hereditary Breast and Ovary Cancer Syndrome genetic
test criteria compared to healthy woman (controls). TP53 p.R337H mutation status was determined using the High
Resolution Melting (HRM) method, followed by DNA sequencing. Fisher’s test was used to compare the prevalence
of TP53 p.R337H in the patient and control groups.
Results: Two of the breast cancer cases (7.1%) and none of the controls carried the TP53 p.R337H mutation. At the
time of the investigation, both cases fulfilled testing criteria for Hereditary Breast and Ovary Cancer Syndrome but
not Li-Fraumeni or Li-Fraumeni-like Syndrome, based on genetic testing criteria of NCCN Clinical Practice Guidelines
in Oncology (v.1.2010).
Conclusions: We suggest that genetic screening of Brazilian breast cancer patients who fulfill Hereditary Breast and
Ovary Cancer Syndrome criteria and have a family history that includes other tumors of the LFS/LFL spectrum be
tested for the TP53 p.R337H mutation.
Keywords: Breast cancer, TP53 mutation, BRCA1, High resolution melting
Background
The World Health Organization (WHO) estimates that
over one million women are affected annually by breast
cancer [1]. In Brazil, breast cancer is the most prevalent
cause of death due to cancer among women from 40 to
69 years old [2]. About 5-10% of breast cancers are
hereditary, and approximately 30% of young women
who develop this type of cancer have a predisposition to
disease [3-6]. Two major hereditary cancer predisposition
syndromes are related to hereditary breast cancer pheno-
type: Hereditary Breast and Ovarian Cancer Syndrome
(HBOC) and Li-Fraumeni Syndrome (LFS). HBOC is due
to mutations in the BRCA1 and BRCA2 genes; it is charac-
terized by ductal or lobular breast adenocarcinoma and
epithelial ovarian carcinoma [7].
In 1990, LFS was found to be associated with germline
mutations in TP53 [8]. Pathogenic mutation carriers for
this gene have a cumulative risk of up to 90% for the de-
velopment of a cancer spectrum, which is usually diag-
nosed before the age of 45. The most frequent cancer
types include sarcoma, breast cancer, brain tumors,
leukemia and adrenocortical carcinomas. Other cancers
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are observed at a lower frequency, including lymphomas,
gastric cancer and melanoma [9,10]. Families that do not
have the classic phenotype of this syndrome are called
Li-Fraumeni like (LFL) or Li-Fraumeni variant (Table 1)
[11-13]. The NCCN Clinical Practice Guidelines in On-
cology v.4.2013 take into account only classic LFS and
Chompret criteria for LFS/LFL genetic testing [14].
Given the similar mutation rates of the BRCA1, BRCA2
and TP53 genes, Lee et al. [15] proposed that women who
developed breast cancer before 30 years of age should
undergo genetic testing for all three genes simultaneously.
Custodio et al. (2013) estimated an overall frequency of
0.2-0.3% for TP53 p.R337H in a southern Brazil state
[16]. This mutation has been identified in >90% of
Brazilian patients with childhood adrenocortical carcin-
oma, a rare but remarkably frequent tumor in south-
eastern and southern Brazil [16]. It also has been
proposed that this mutation increases breast cancer risk
in women, especially in southern Brazil [17-19]. The
frequency of TP53 p.R337H in women with breast can-
cer has been reported as 2.4% [18], while in healthy
women it is only 0.3% [20].
Given this potential association with breast cancer and
the high frequency of TP53 p.R337H in southern Brazil,
we conducted a case-control study to compare TP53 p.
R337H mutation prevalence in healthy controls with that
in female breast cancer patients in Ribeirão Preto, Sao
Paulo state, located in southeast Brazil. The affected
women fulfilled HBOC genetic test criteria, according
to NCCN Clinical Practice Guidelines in Oncology
v.1.2010 [21].
Methods
Subjects
This study was approved by the Ethics Committee of
the University of Sao Paulo Medical School of Ribeirão
Preto, SP, Brazil; informed consent was obtained from
participants. We analyzed 28 DNA samples of unrelated
women diagnosed with breast cancer that fulfilled the
criteria for HBOC genetic testing according to NCCN
Clinical Practice Guidelines in Oncology v.1.2010 [21]
(Table 2). All patients were enrolled in the Cancer
Genetic Counseling Service of the General Hospital of
the University of São Paulo Medical School of Ribeirão
Preto (HCFMRP-USP).
The control group was formed by 120 healthy women,
age-matched to cases (Table 3), without family history of
cancer, randomly selected among women attended at
HCFMRP-USP and unrelated to the patients.
Sample collection
Peripheral blood samples (10 mL) were collected into
vacutainer tubes containing EDTA, while they were
attended at the clinic. Genomic DNA was extracted using
the Wizard Genomic DNA Purification Kit (Promega,
Madison, WI, USA), following the manufacturer’s recom-
mendations and stored at -20°C until genotyping analysis.
The samples were collected from March 2009 to June
2010.
Genotype determination
High Resolution Melting (HRM)
The HRM method was used to detect the TP53 p.R337H
mutation. The HRM primer sequences were as described
by Bastien et al. [22]. Reactions were performed with a
total volume of 20 uL (3.6 uL of MiliQ water, 1.2 mL of
each primer at 5 pmol/uL, 10 uL of MeltDoctor
HRMTM Master Mix (Applied Biosystems) and 4 uL of
DNA at 5 ng/uL). The amplification parameters were:
95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and
annealing temperature for 1 minute. For melting curve
analysis, the parameters were: 95°C for 10 seconds, 60°C
Table 1 Current genetic testing criteria for LFS
Classification Description
Classic (Li et al., 1988) [25] Proband diagnosed with sarcoma before age 45, and a FDR with cancer before age 45, and another first- or
second-degree relative with any cancer diagnosed under age 45 or with sarcoma at any age
Birch (Birch et al.,1994) [11] Proband with any childhood cancer or sarcoma, brain tumor, or adrenocortical carcinoma diagnosed under
45 years, and a FDR or SDR with a typical Li-Fraumeni syndome-related cancer (sarcoma, breast cancer, brain tumor,
leukemia, or adrenocortical carcinoma) diagnosed at any age and an FDR or SDR in the same genetic lineage with
any cancer diagnosed under the age of 60
Eeles (Eeles, 1995) [12] Two different tumors that are part of the extended Li-Fraumeni syndome in FDR or SDR at any age (sarcoma, breast
cancer, brain tumor, leukemia, adrenocortical tumor, melanoma, prostate cancer, and pancreatic cancer)
Revised Chompret
(Tinat et al., 2009) [26]
I—Proband diagnosed with tumor belonging to Li-Fraumeni syndome spectrum (soft tissue sarcoma, osteosarcoma,
brain tumor, premenopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before
age 46 and at least one first- or second degree relative with Li-Fraumeni syndrome cancer (except breast cancer if
the proband has breast cancer) under the age of 56 years or with multiple tumors at any age
II—Proband with multiple primary tumors (except multiple breast), two of which belong to Li-Fraumeni syndome
tumor spectrum and the first of which occurred before age 46
III—Proband with adrenocortical carcinoma or choroid plexus tumor at any age, irrespective of family history
FDR, First-degree relative; SDR, Second-degree relative.
Cury et al. Hereditary Cancer in Clinical Practice 2014, 12:8 Page 2 of 8
http://www.hccpjournal.com/content/12/1/8
for 1 minute, 95°C for 15 seconds and 60°C for 15 seconds.
The samples with different melting curves were sequenced
to validate and characterize the mutation.
DNA sequencing
For TP53, the different melting curve fragments were
sequenced in an automatic sequencer XL 3500 Genetic
Analyzer (Applied Biosystems). The reaction consisted
of 1 to 2 uL of amplified DNA, 2 uL of Big Dye Termin-
ator v3.1 Cycle, 2 uL of 5X Sequencing Buffer (Applied
Biosystems), 1 uL of primer and sufficient water to
complete 10 uL. The amplification parameters of the
sequencing reaction were: 95°C for 1 minute followed
by 25 cycles of 95°C for 10 seconds, 50°C for 5 seconds
and 60°C for 4 minutes.
The complete coding sequence and exon-intron bound-
aries of BRCA1 and BRCA2 were analyzed in two TP53
p.R337H positive females. The sequences of the primers
were those described by Leeneer et al. [23], and Keshavarzi
et al. [24], respectively.
Statistical analyses
The TP53 p.R337H mutation frequency in breast cancer
patients and controls was compared using Fisher’s exact
test with GraphPad Prism 5 software to calculate odds
ratios (OR), with confidence intervals (CIs) of 95%. A
p-value of <0.05 was considered to be statistically sig-
nificant. The TP53 p.R337H frequency in breast cancer
patients was compared to the estimated Brazilian popula-
tion frequency [16], which we assumed to be the true
prevalence rate for the Brazilian population, using the
one-sided exact test for binomial proportions.
Results
Twenty-eight women diagnosed with breast cancer were
tested for TP53 mutations; two of them (7.1%) were
found to carry a pathogenic mutation, heterozygous TP53
p.R337H (Figure 1). Both are negative for BRCA1 and
BRCA2 pathogenic mutations. TP53 p.R337H is known
to be more frequent in women with breast cancer, espe-
cially in families in southern Brazil suspected to have
Li-Fraumeni Syndrome [17].
Patient 1 was diagnosed with parotid cancer at age 60
and bilateral breast cancer at age 61 in the left breast
and age 62 in the right breast. Her brother had Central
Nervous System cancer at age 58. Nevertheless, she did
not meet the criteria for Li-Fraumeni Syndrome according
to NCCN Guidelines v.1.2010 [21] and v.4.2013 [14], be-
cause the tumors related to the Li-Fraumeni Syndrome
spectrum, in this case breast and prostate cancer, were di-
agnosed in third degree relatives (Figure 2). In the context
of HBOC, she fulfilled the criteria of bilateral breast
cancer personal history at any age, as two third-degree
relatives were also diagnosed with breast cancer (Table 2).
Patient 2 was diagnosed with breast cancer at age 30.
Her sister and her cousin were diagnosed with breast
cancer at ages 42 and 35, respectively. Both had the
same TP53 mutation; they were heterozygous for TP53
p.R337H. Additionally, her uncle was diagnosed with
prostate cancer after he turned 60. Other tumors that
are not part of the Li-Fraumeni Syndrome spectrum
were diagnosed in second and third-degree relatives
(Figure 3). There were two HBOC criteria for this pa-
tient: breast cancer personal history before 45 years old
and family history of breast cancer before 50 years old;
one first-degree relative and one third-degree relative
were diagnosed with breast cancer before they were 50
(Table 2).
Table 2 Patient criteria for genetic testing according to NCCN clinical practice guidelines in oncology v.1.2010 [21] for
HBOC
Patient 1 Patient 2 Criteria
X Personal history of breast cancer ≤ 45 years
Personal history of two primary breast cancers, the first being diagnosed before 50 years of age
Personal history of breast cancer with age at diagnosis < 50 years with limited family history
X Personal history of breast cancer ≤ 50 years with ≥ 1 relative with breast cancer ≤ 50 years and/or ≥ 1
relative with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at any age
Personal history of triple-negative breast cancer, with age at diagnosis < 60 years
X Personal history of breast cancer at any age, with ≥ 2 relatives with breast cancer and/or epithelial ovarian
cancer, fallopian tube cancer, or primary peritoneal cancer at any age
Personal history of breast cancer + Personal history of epithelial ovarian cancer, fallopian tube cancer,
or primary peritoneal cancer
Table 3 Patient and control group clinical features
Features Patient group Control group
Number 28 120
Age (years) 41.75 (±10.25) 41.95 (±10.58)
Gender F: 28 (100%) F: 120 (100%)
F, Female.
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The HBOC criteria fulfilled for all 28 patients based
on NCCN Guidelines v1.2010 [21] continued without
change in v4.2013 [14].
Though both patients had a family history that included
other tumors at the time of investigation, they did not ful-
fill the criteria for Li-Fraumeni Syndrome, according to
NCCN Clinical Practice Guidelines in Oncology v.1.2010
[21]. However, the v.4.2013 [14] of these guidelines
(Table 4) indicated that individuals with breast cancer by
35 years of age, not before 30 years of age as in previous
version, and negative for BRCA1/2 fulfills LFS testing
criteria. Consequently, according to the latest NCCN
guidelines, patient 2 fulfills the criteria for LFS. In
addition to the classic LFS [25] and Chompret [26] cri-
teria, there are two more clinical criteria, called Birch
[11] and Eeles [12]. Patient 1 just meets Eeles criteria
for LFL, the less stringent one.
In comparison with the two of 28 HBOC breast cancer
women patients who had the TP53 p.R337H mutation,
none of the 120 healthy women without family history
of cancer had this mutation. We found a significant as-
sociation of TP53 p.R337H mutation with breast cancer
(p = 0.0347; Table 5). Comparing our results with the
overall frequency of TP53 p.R337H in southern Brazil,
assumed by Custodio et al. (2013) to be in the range of
0.2–0.3% [16], we found that the TP53 p.R337H mutation
frequency was significantly higher among breast cancer
women with HBOC than in the general Brazilian popula-
tion (p = 0.001 and 0.003 in comparison to 0.2 and 0.3%,
respectively; one-sided exact binomial test).
Discussion
Based on our study, we suggest that TP53 p.R337H mu-
tation prevalence in breast cancer patients suspected of
Figure 1 TP53 p.R337H mutation detection. A) Melting curves for each specific genotype identified in exon 10 of the TP53 gene containing
the TP53 p.R337H mutation; B) Sequencing results of a heterozygous TP53 p.R337H mutation sample (melting curve in blue) and a wild type
sample (melting curves in green).
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HBOC in Ribeirão Preto, São Paulo, Brazil is high
(7.1%). This result falls within the range of that found in
previous studies conducted in southern Brazil (2.4-13%)
[17,18]. However, the study by Achatz et al. is based on
LFS/LFL families with tumors other than breast cancer.
This mutation is responsible for exchanging an argin-
ine for a histidine (CGC to CAC) at codon 337, located
at an oligomerization domain of p53 protein. It has
been primarily associated with adrenocortical tumors in
children [27,28].
Contact of alpha-helices of two adjacent monomers
through a hydrogen bond is critical to oligomer stability
and hence for p53 binding to DNA. Because histidine
pKa is lower than arginine pKa, increased pH conditions
Figure 2 Pedigree of patient 1, showing cancer history and the TP53 p.R337H mutation. Arrow indicates the proband; present age or age
at death is indicated below individuals. The cancer diagnosis age is indicated in brackets. wt = wild type.
Figure 3 Pedigree of patient 2, showing cancer history and the TP53 p.R337H mutation. Arrow indicates the proband; present age or age
at death is indicated below individuals. The cancer diagnosis age is indicated in brackets. wt = wild type.
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(pH 8.3) cause histidine deprotonation, making it incap-
able of forming a hydrogen bond, consequently prevent-
ing protein binding to DNA [27,29]. However, the
pathogenicity of TP53 p.R337H is still questionable due
to the low number of functional studies.
Achatz et al. (2007) [17] screened for the TP53 p.R337H
mutation in 45 Brazilian subjects from unrelated families
with cancer histories suggestive of LFS. They found the
mutation in six cases (13%). Interestingly, the most
common tumor type in these families was breast cancer
(30.4%).
Assumpção et al. (2008) [18] estimated the prevalence
of this mutation in 123 breast cancer cases and 223 age-
matched controls. Three of the cases (2.4%) and none of
the controls were carriers of the TP53 p.R337H muta-
tion (P = 0.04). All three cases were relatively young at
diagnosis (range 19-44 years old), and two of the three
cases had a family history suggestive of LFS.
The role of the TP53 p.R337H mutation in breast car-
cinogenesis is still unclear. Achatz et al. (2007) found that,
in an invasive ductal breast adenocarcinoma sample, the
TP53 p.R337H mutation was homozygous in tumor tissue
and heterozygous in peripheral blood, suggesting a role in
tumor development. However, Assumpção et al. (2008)
found the mutant TP53 p.R337H allele to be absent in the
three breast tumors examined.
Gomes et al. (2012) [30] evaluated TP53 p.R337H muta-
tion frequency in 390 unselected breast cases and 324 con-
trols from Rio de Janeiro state. Two of the breast cancer
cases (0.5%) and none of the controls carried the mutation.
Both cases had an early age at diagnosis (<40 years old) and
a family history including breast and other cancer types.
Our study shows that TP53 p.R337H is found in women
who fulfill HBOC genetic testing criteria but not the LFS
criteria, according to NCCN Clinical Practice Guidelines in
Oncology v.1.2010 [21]. The change made in v.4.2013 [14]
of these guidelines led us to include patient 2 in LFS genetic
testing criteria, but not patient 1. This patient potentially
fulfills the Eeles criteria, which is not included in NCCN
testing criteria. This fact, associated with the apparently
high frequency of TP53 p.R337H mutation in the popula-
tion that we analyzed, reinforces the necessity of adjusting
genetic testing criteria for hereditary syndromes according
to local populations characteristics.
It has been suggested that TP53 genetic testing should be
considered for women diagnosed with breast cancer under
age 30 after they have previously tested negative for muta-
tions in BRCA1 and BRCA2 [31]. However, given similar
mutation rates in early breast cancer, Lee et al. (2012) [15]
proposed that these women should undergo genetic testing
for mutations in all three genes at the same time. Taking
into account the high frequency of the TP53 p.R337H mu-
tation in Brazilian women with breast cancer [17,18,20,30],
and given that the TP53 p.R337H genetic test (single nu-
cleotide change at codon 337) is easy, fast and inexpensive,
we suggest that the TP53 p.R337H mutation screening
should not be restricted to early breast cancer patients,
but to all Brazilian breast cancer patients with a family his-
tory that includes other LFS/LFL tumors.
One important limitation of our study is the relatively
small number of subjects. Nevertheless, the association
of TP53 p.R337H mutation with breast cancer that we
found is enough to lead us to suggest that TP53 p.R337H
mutation screening should be conducted at the same time
as BRCA testing and not necessarily only after patients
have previously tested negative for BRCA gene mutations.
This could speed up diagnosis of breast cancer and help
optimize genetic counseling procedures.
Table 4 Genetic testing criteria according to NCCN clinical practice guidelines in oncology v.4.2013 [14] for LFS
Criteria Description
Familial TP53
mutation Individual from a family with a known TP53 mutation
Early-onset breast
cancer Personal history of breast cancer ≤ 35 years of age with a negative BRCA1/2 test
Classic LFS criteria Personal history of sarcoma < 45 years + 1 first-degree relative with cancer diagnosed at age <45 years + 1 first- or second-
degree relative in the same lineage with cancer diagnosed at age < 45 years or sarcoma at any age
Chompret criteria Personal history of a tumor of the LFS spectrum (eg. soft tissue sarcoma, osteosarcoma, brain tumor, breast cancer,
adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before 46 years of age + at least one first- or second-
degree relative with any of the aforementioned cancers (other than breast cancer if the proband has breast cancer) before
the age of 56 years or with multiple primaries at any age
Personal history of multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum, with
the initial cancer occurring before the age of 46 years
Personal history of adrenocortical carcinoma or choroid plexus carcinoma at any age of onset, regardless of family history
LFS, Li-Fraumeni Syndrome.
Table 5 TP53 P.R337H frequency in breast cancer
patients with HBOC criteria and control groups
TP53
P.R337H
Control
(n = 120)
Breast cancer
(n = 28)
P OR 95% CI
Arg/Arg 120 (100%) 26 (92.9%) 0.0347 0.0439 (0.0020
to 0.9438)
Arg/His 0 2 (7.1%)
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Conclusions
Our study shows that TP53 p.R337H mutation preva-
lence in breast cancer patients suspected of Hereditary
Breast and Ovary Cancer Syndrome in Ribeirão Preto,
São Paulo, Brazil is high (7.1%) and could play an import-
ant role in predisposition to breast cancer in this popula-
tion. However, there is currently no robust evidence for a
role of this mutation in breast carcinogenesis.
We propose that TP53 p.R337H mutation screening be
conducted in Brazilian women who have been diagnosed
with breast cancer at any age, who fulfill Hereditary Breast
and Ovary Cancer Syndrome genetic testing criteria and
have a family history that includes other tumors of the
LFS/LFL spectrum.
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